drugset / Trial / NCT05700656
Galunisertib Combined With Capecitabine in Advanced CRC With PM
NaSingle-groupOpen-labelTreatment
Summary
This is a two-center open-label non-randomized proof of principle study consisting of a dose-finding part (phase I) and phase II study with Simon two-stage design investigating the anti-tumor activity of the combination of capecitabine and galunisertib in patients with colorectal cancer with peritoneal metastases.
Timeline
- Start
- 2023-07-28
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1000 mg/m2 | — |
| Subject | Galunisertib | Small molecule | 150 mg | — |